Of course it is my theory, but it is a theory that fits the data we have: 1. Recruitment was very slow. 2. The trial was stopped early for futility. 3. The pilot trial showed amazing results well in excess of that required for success. If you have a better theory that explains these three data points I am interested to hear.
I didn’t say that MSB’s cells work or not for ARDS, just that the only data we have is they don’t work. The cells might work or they might not, but nobody knows at this point.
Novartis deal on the rocks, page-130
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |